Fibrosarcoma Drugs Market Trends Estimates High Demand by 2026

Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming connective tissue called as fibroblasts.

Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming connective tissue called as fibroblasts. Although, this condition can occur at any age, it is commonly diagnosed between the age of 30-60 years. Patients suffering from genetic conditions such as retinoblastoma, nevoid basal cell carcinoma syndrome are more prone to develop fibrosarcoma. However, precise cause of disease is unknown. Furthermore, individuals undergoing radiation therapy or having lymphedema or get exposed to chemicals such as thorium dioxide vinyl chloride or arsenic are more prone to fibrosarcoma. This disease is symptomized by muscular pain, which increases exponentially with time. Click To Read More On Fibrosarcoma Drugs Market.

It is diagnosed by bone lesions in radiograph, followed by advanced imaging and laboratory test and confirmed by biopsy results. Treatment of the disease depends on the stage of tumour during diagnosis. Surgery and radiation therapy are the treatment used for fibrosarcoma. Currently, limited number of treatment methods and various side effects of chemotherapy such as hair loss or low blood platelet count are propelling demand for research and development activities in fibrosarcoma treatment.

Fibrosarcoma Drugs Market Driver

Increasing research activities are expected to fuel the growth of fibrosarcoma drugs market over the forecast period. Fibrosarcoma being malignant tumor requires early removal through complete eradication of malignant cells by chemotherapy. Currently available chemotherapy includes side-effects such as acquirance of multi-drug resistance (MDR), severe side-effects and high rate of reoccurrence, which in turn demands for safer drug for chemotherapy. For instance, Loxo Oncology Inc., 2017, received US FDA approval for investigational new drug application for LOXO 195, a next-generation TRK inhibitor for treatment of patients with cancers that have acquired resistance to initial TRK therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced partnership with Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel drug combination studies, clinical trial for targeted drug delivery and genetic profile based medication are expected to boost growth of the fibrosarcoma drugs market over the forecast period.

Increasing prevalence of fibrosarcoma is expected to augment growth of the fibrosarcoma drugs market. According to American Society of Clinical Oncology, 2017, around 3260 individuals were diagnosed by primary bone cancer in U.S. out of which 4% of adults are suffering from fibrosarcoma and prevalence of the disease is higher in men than in women. Currently, diagnosis facility lacks in early and accurate detection of fibrosarcoma. Therefore, rising awareness for disease and advancement in diagnostic as well as therapeutic procedures are expected to propel growth of the fibrosarcoma drugs market. Furthermore, companies, universities, and institutes are taking initiatives to provide inexpensive, readily available drugs with less side-effects as compared to present drugs that will help key players to strengthen product portfolio, in turn driving growth of the fibrosarcoma drug market. Key players as well as government organization such as Nation Cancer Institute or American Society of Clinical Oncology sponsors or collaborate for the development of novel therapies and drugs. For instance, Bayer partners with loxo oncology to develop and commercialise cancer therapies.

Fibrosarcoma Drugs Market- Regional Analysis

The global fibrosarcoma market is projected to hold dominant position in North America over the forecast period, due to increasing research activities leading to better fibrosarcoma treatment. Furthermore, well-developed healthcare infrastructure is fuelling growth of fibrosarcoma market. Asia Pacific is expected to be fastest growing market over the forecast period due to developing healthcare infrastructure and rising awareness regarding conditions of fibrosarcoma.

Auto-injector is a needle based medical device which is used for the administration of a fixed dose of a particular drug. It can be used for self-administration by the patients or untrained person, as it is easy to handle.

Non-vascular stents are mainly shielded with a polymeric film or membrane to avoid ingrowth of adjacent tissues through stent mesh. Drugs for suppression of hyperplastic malignant or benign tissues can be integrated into polymeric materials.

ECG management system is a web-based electronic medical record that offers better workflow efficiency by processing, storing, and distributing the cardiovascular information between doctors and patients.

Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure.

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations.

Influenza is contagious respiratory disease that is caused by influenza viruses and can lead to hospitalization and even death in certain severe cases. Influenza virus infect the respiratory tract (nose, throat, and lungs) in humans.

Shell component and composition are important factors while manufacturing empty capsules. Gelatin or a non-gelatin polymeric material such as hypromellose, water, starch, and plasticizer is used in manufacturing hard o​r soft gelatin capsule shells.

Digital health is a new age platforms that deals with prime focus on consumer centric healthcare approach which results in efficient and quality healthcare at much lesser cost than traditional healthcare ecosystem

Intracranial stents are used for intracranial stenosis and brain aneurysms to open the blocked arteries. This procedure is relatively new for these conditions and long-term enhanced results for placement of these stents alone is still under investigation.

Ostomy refers to a surgical procedure that allows the passage of bodily wastes through a surgically created stoma or aperture on the abdomen into a prosthetic such as a pouch or bag placed outside the body.